Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Free Cash Flow of -$19.6 million for Q1 2026, up 7.12% year-over-year from -$18.3 million in Q1 2025, and up 5.99% quarter-over-quarter from -$20.8 million in Q4 2025.

Analysis

Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026) Analysis & Trends

Oculis Holding AG's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$19.6 million for Q1 2026.

  • In Q1 2026, Free Cash Flow rose 7.12% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$77.7 million (down 28.08% YoY), while the FY2025 annual figure was -$79.6 million, down 43.84% from the prior year.
  • Free Cash Flow for Q1 2026 stood at -$19.6 million, up from -$20.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$5.2 million in Q4 2022, with the low at -$21.1 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$15.7 million (2024), against an average of -$15.1 million.
  • The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 210.52% in 2023, then climbed 24.53% in 2024.
  • Oculis Holding AG's Free Cash Flow stood at -$5.2 million in 2022, then plunged by 210.52% to -$16.0 million in 2023, then gained by 24.53% to -$12.1 million in 2024, then slumped by 72.3% to -$20.8 million in 2025, then grew by 5.99% to -$19.6 million in 2026.
  • Business Quant data shows OCS's Free Cash Flow at -$19.6 million in Q1 2026, -$20.8 million in Q4 2025, and -$16.6 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.01 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 572.80 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -563.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -389.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 437.80 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 292.04 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 477.44 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -95.09 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - -25.96 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -25.96 Mn
Mar 31, 2026 -19.83 Mn
Dec 31, 2025 -21.39 Mn
Sep 30, 2025 -16.46 Mn
Jun 30, 2025 -20.99 Mn
Mar 31, 2025 -21.42 Mn
Dec 31, 2024 -13.19 Mn
Sep 30, 2024 -11.78 Mn
Jun 30, 2024 -15.66 Mn
Mar 31, 2024 -15.73 Mn
Dec 31, 2023 -16.50 Mn
Sep 30, 2023 -13.55 Mn
Jun 30, 2023 -14.71 Mn
Mar 31, 2023 -16.89 Mn
Dec 31, 2022 -6.77 Mn
Sep 30, 2022 -7.14 Mn